GE

221.63

+1.31%↑

RTX

130.89

+0.18%↑

CAT

353.51

+3.18%↑

BA

203.65

+2.65%↑

HON

218.59

-0.27%↓

GE

221.63

+1.31%↑

RTX

130.89

+0.18%↑

CAT

353.51

+3.18%↑

BA

203.65

+2.65%↑

HON

218.59

-0.27%↓

GE

221.63

+1.31%↑

RTX

130.89

+0.18%↑

CAT

353.51

+3.18%↑

BA

203.65

+2.65%↑

HON

218.59

-0.27%↓

GE

221.63

+1.31%↑

RTX

130.89

+0.18%↑

CAT

353.51

+3.18%↑

BA

203.65

+2.65%↑

HON

218.59

-0.27%↓

GE

221.63

+1.31%↑

RTX

130.89

+0.18%↑

CAT

353.51

+3.18%↑

BA

203.65

+2.65%↑

HON

218.59

-0.27%↓

Search

Ocugen Inc

Cerrado

0.69

Resumen

Variación precio

24h

Actual

Mínimo

0.66

Máximo

0.71

Métricas clave

By Trading Economics

Ingresos

-1.5M

-15M

Ventas

717K

1.5M

BPA

-0.05

Margen de beneficios

-1,036.462

Empleados

95

EBITDA

-1.3M

-15M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+804.29% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

28M

204M

Apertura anterior

0.69

Cierre anterior

0.69

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Ocugen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 may 2025, 23:20 UTC

Ganancias

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

13 may 2025, 23:48 UTC

Charlas de Mercado

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

13 may 2025, 23:43 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 may 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

13 may 2025, 23:24 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

13 may 2025, 23:24 UTC

Charlas de Mercado
Ganancias

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

13 may 2025, 22:58 UTC

Ganancias

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 may 2025, 22:58 UTC

Ganancias

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 may 2025, 22:58 UTC

Ganancias

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

13 may 2025, 22:58 UTC

Ganancias

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

13 may 2025, 22:38 UTC

Ganancias

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

13 may 2025, 22:38 UTC

Ganancias

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

13 may 2025, 22:37 UTC

Ganancias

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

13 may 2025, 22:36 UTC

Ganancias

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

13 may 2025, 22:35 UTC

Ganancias

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

13 may 2025, 22:34 UTC

Ganancias

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

13 may 2025, 22:33 UTC

Ganancias

Aristocrat: Interactive Business Delivered Strong Revenue Growth

13 may 2025, 22:33 UTC

Ganancias

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

13 may 2025, 22:33 UTC

Ganancias

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

13 may 2025, 22:30 UTC

Ganancias

Aristocrat Interim Dividend 44 Australian Cents/Share

13 may 2025, 22:30 UTC

Ganancias

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

13 may 2025, 22:29 UTC

Ganancias

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

13 may 2025, 22:28 UTC

Ganancias

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

13 may 2025, 21:15 UTC

Ganancias

Nu Holdings 1Q Rev $3.2B >NU

13 may 2025, 21:03 UTC

Principales Noticias

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

13 may 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

13 may 2025, 20:32 UTC

Ganancias

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13 may 2025, 20:31 UTC

Ganancias

Alcon 1Q Sales $2.45B >ALC.EB

13 may 2025, 20:30 UTC

Ganancias

Alcon 1Q Rev $2.47B >ALC.EB

13 may 2025, 20:30 UTC

Ganancias

Alcon 1Q EPS 70c >ALC.EB

Comparación entre iguales

Cambio de precio

Ocugen Inc previsión

Precio Objetivo

By TipRanks

804.29% repunte

Estimación a 12 Meses

Media 6.33 USD  804.29%

Máximo 8 USD

Mínimo 4 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ocugen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

0.6818 / 0.74Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.